BackVolitionRX Overview

VolitionRX Profit Margin

Valuation check: VNRX's profit margin is -997.46%, below the Healthcare sector average of 15.29%.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

-676.57%
69.27% YoY

As of Mar 2026

Annual Profit Margin (TTM)

-997.46%
45.68% YoY

Trailing 12 months ending Mar 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

VolitionRX (VNRX) FAQ

VolitionRX (VNRX) currently reports a profit margin of -997.46% as of March 2026. That compares with -1836.21% in the prior-year period — up 45.7% year over year. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore VolitionRX's profit margin history and peer comparisons.

VolitionRX's profit margin increased from -1836.21% to -997.46% — a 45.7% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

VolitionRX's profit margin of -997.46% is lower than the Healthcare sector average of 15.29%. That is roughly 6622.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but VolitionRX's current -997.46% should be judged against Healthcare norms (sector average: 15.29%) and against VNRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -997.46%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for VolitionRX, and consider following VNRX for alerts when major investors trade the stock.